



901 California Avenue

Palo Alto, CA 94304-1104

Main: 650 • 496-6400

FAX: 650 • 496-1200

FAX TRANSMITTAL SHEETNO. OF PAGES (including this page): 7

TO: Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Attn: Examiner P. Mertz
Art Unit: 1646
FAX: (571) 273-0876

FROM: Sheela Mohan-Peterson
DATE: February 17, 2004
RE: Docket No.: DX0644KBK
USSN: 10/083,720
Filed: February 28, 2002
Title: Mammalian Cytokines; Related Reagents

Any difficulty with this facsimile, please call:
Sheela Mohan-Peterson at (650) 496-1244

Documents attached:

- Transmittal (1 page)
- Second Preliminary Amendment (5 pages)

I hereby certify that this correspondence is being transmitted by facsimile to the U.S. Patent and Trademark Office, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, Fax Number (571) 273-0876, Attention: Examiner P. Mertz; Art Unit 1646, on February 17, 2004.

A handwritten signature in cursive script, appearing to read "Sheela Mohan-Peterson".
Sheela Mohan-Peterson

CONFIDENTIALITY NOTE: This sheet and/or the document(s) accompanying it contain information belonging to DNAX which is confidential and/or legally privileged. The information is intended only for the use of the person or entity named above. If you have received this fax in error, please immediately notify us by telephone or return Fax.

PTO/SB/21 (03-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

| | | | |
|---|--|------------------------|----------------------|
| TRANSMITTAL FORM (to be used for all correspondence after initial filing) | | Application Number | 10/083,720 |
| | | Filing Date | February 28, 2002 |
| | | First Named Inventor | Rene de Waal Malefyt |
| | | Art Unit | 1646 |
| | | Examiner Name | P. Mertz |
| Total Number of Pages In This Submission | | Attorney Docket Number | DX0644KBK |

ENCLOSURES (Check all that apply)

| | | |
|--|--|---|
| <input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ | <input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): |
| Remarks: 1. Preliminary Amendment #2 (5 pages) 2. Fax Transmittal Sheet (1 page) | | |

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

| | |
|--------------------|--|
| Firm or Individual | Sheela Mohan-Peterson, Reg. No. 41,201 DNAX Research, Inc. 901 California Ave. Palo Alto, CA 94304-1104 |
| Signature | <i>Sheela Mohan-Peterson</i> |
| Date | 17-Feb-2004 |

CERTIFICATE OF TRANSMISSION

| | | | |
|---|------------------------------|------|-------------|
| I hereby certify that this correspondence is being facsimile transmitted to the USPTO to the U.S. Patent and Trademark Office, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, FAX number (571) 273-0876, Attention: Examiner P. Mertz. | | | |
| Typed or printed | Sheela Mohan-Peterson | | |
| Signature | <i>Sheela Mohan-Peterson</i> | Date | 17-Feb-2004 |

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Appl. No. 10/083,720

Attorney Docket: DX0644KBK

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re application of:

Rene de Waal Malefyt, et al.

Application No.: 10/083,720

Filing Date: February 28, 2002

For: Mammalian Cytokine; Related
Reagents

Examiner: P. MERTZ

Art Unit: 1646

Confirmation No. 1917

I hereby certify that this correspondence is being transmitted by
facsimile to the U.S. Patent and Trademark Office, Commissioner for
Patents, P.O. Box 1450, Alexandria, VA 22313-1450,
Fax Number (571) 273-0876, Attention: Examiner P. Mertz,
Art Unit 1646, on February 17, 2004.

by:


Sheela Mohan-Paterson

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PRELIMINARY AMENDMENT NUMBER 2

Sir:

Please amend the above-referenced patent application as follows:

Amendments to the Claims are reflected in the listing of claims that begins on
page 2 of this paper.

Remarks begin on page 5 of this paper.